In this thesis, molecular dynamics simulations, molecular docking, and homology modeling methods have been used in combination to design possible inhibitors as well as to study the structural changes and function of target proteins related to diseases that today are in the spotlight of drug discovery. The inwardly rectifying potassium (Kir) channels constitute the first target in this study; they are involved in cardiac problems. On the other hand, tensin, a promising target in cancer research, is the second target studied here. The first chapter includes a brief update on computational methods and the current proposal of the combination of MD simulations and docking techniques, a procedure that is applied for the engineering of a new blocker for Kir2.1 ion channels and for the design of possible inhibitors for Tensin. Chapter two focuses in Kir ion channels that belong to the family of potassium-selective ion channels which have a wide range of physiological activity. The resolved crystal structure of a eukaryotic Kir channel was used as a secondary structure template to build the Kir-channels whose crystallographic structures are unavailable. Tertiapin (TPN), a 21 a.a. peptide toxin found in honey bee venom that blocks a type of Kir channels with high affinity was also used to design new Kir channel blockers. The computational methods homology modeling and protein-protein docking were employed to yield Kir channel-TPN complexes that showed good binding affinity scores for TPN-sensitive Kir channels, and less favorable for Kir channels insensitive to TPN block. The binding pocket of the insensitive Kir-channels was studied to engineer novel TPN-based peptides that show favorable binding scores via thermodynamic mutant-cycle analysis. Chapter three is focused on the building of homology models for Tensin 1, 2 and 3 domains C2 and PTP using the PTEN X-ray crystallographic structure as a secondary structure template. Molecular docking was employed for the screening of druggable small molecules and molecular dynamics simulations were also used to study the tensin structure and function in order to give some new insights of structural data for experimental binding and enzymatic assays. Chapter four describes the conformational changes of FixL, a protein of bradyrhizobia japonicum. FixL is a dimer known as oxygen sensor that is involved in the nitrogen fixation process of root plants regulating the expression of genes. Ligand behavior has been investigated after the dissociation event, also the structural changes that are involved in the relaxation to the deoxy state. Molecular dynamics simulations of the CO-bound and CO-unbound bjFixL heme domain were performed during 10 ns in crystal and solution environments then analyzed using Principal Component Analysis (PCA). Our results show that the diffusion of the ligand is influenced by internal motions of the bound structure of the protein before CO dissociation, implying an important role for Arg220. In turn, the location of the ligand after dissociation affects the conformational changes within the protein. The study suggests the presence of a cavity close to the methine bridge C of the heme group in agreement with spectroscopic probes and that Arg220 acts as a gate of the heme cavity.

The ability to adhere to the extracellular matrix (ECM) is critical for numerous cell types and tissues including epithelia and muscle. Cell-ECM adhesion is primarily mediated by integrins which provide a direct link between the ECM and the actin cytoskeleton. Integrin adhesions are frequently associated with a core of 60 different proteins (integrin-associated proteins, IAPs). Integrins are required for muscle attachment and in Drosophila, loss of integrins and several IAPs results in embryonic lethality and muscle detachment. However, the IAPs FAK, RSU1, tensin, vinculin and zyxin are not required for viability or embryonic muscle attachment. Furthermore, FAK, RSU1, tensin and vinculin have been observed to localise to muscle attachment sites in Drosophila, indicating that they have some function in muscle attachment. Unlike FAK, RSU1, tensin and vinculin, it was not previously known whether zyxin is expressed in Drosophila muscles. To test this, I generated a genomic zyxin-GFP construct that should contain most of the endogenous zyxin promotor. The genomic zyxin-GFP construct was not observed at muscle attachment sites, suggesting that it is not normally expressed in muscle. I wished to know whether FAK, RSU1, tensin and vinculin are required for muscle function. Various behavioural assays were employed to test for muscle function in larvae and adult flies. The results suggest that larval muscle function was normal in flies lacking these IAPs, but that adult muscle function might be impaired, although it proved difficult to demonstrate a clear functional defect. I then tested whether the IAPs FAK, RSU1, tensin and vinculin are required for normal morphology of adult muscles, focusing on the adult indirect flight muscles (IFMs). The IFMs are fibrillar muscles which attach to the cuticle via specialised epithelial cells known as tendon cells. At the end of the myofibril, where the myofibril attaches to the tendon cell, is a dense region of actin and IAPs known as the modified terminal Z-band (MTZ). I have found that the MTZ is not a homogenous zone of proteins, but is instead organised into at least three distinct layers. Because of the similarity between the structure of the MTZ with that of a hand, I refer to the layers as ‘fingers’, ‘palm’ and ‘wrist’. I discovered that the IAPs FAK, RSU1, tensin and vinculin are each required for the proper structure of the MTZ in unique ways. The fingers were elongated in IFMs lacking FAK, RSU1, tensin or vinculin, while the palm was disrupted in IFMs lacking RSU1, tensin or vinculin. Finally, I was intrigued by the enrichment of the actin-binding protein filamin/Cheerio in the palm and wished to know if it is required for palm function. Deletion of the C-terminus of filamin/Cheerio resulted in a reduction in palm length. Filamin/Cheerio is a mechanosensitive protein which exists in a closed and open conformation. I found that filamin/Cheerio must be open in order to help form a normal palm. Furthermore, vinculin is required to convert filamin/Cheerio from and closed to an open filamin/Cheerio state so that it can perform its function in the palm.

Phosphorylation mediated inactivation of PTEN leads to multiple malignancies with increased severity. However, the consequence of such inactivation on downstream functions of PTEN are poorly understood. Therefore, the objective of my thesis is to ascertain the molecular mechanisms by which PTEN phosphorylation drives lung cancer. PTEN phosphorylation at the C-terminal serine/threonine cluster abrogates its tumor suppressor function. Despite the critical role of the PTEN C-tail in regulating its function, the crystal structure of the C-tail remains unknown. Using bioinformatics and structural analysis, I determined that the PTEN C-tail is an intrinsically disordered region and is a hot spot for post-translational modifications (particularly phosphorylation) and protein-protein interactions. Evolutionary analysis of PTEN and its interacting proteins revealed that the PTEN C-tail has only recently evolved to acquire the ability to engage in a myriad of protein-protein interactions, resulting in its versatile functions. Replacement of the PTEN C-tail serine/threonine residues with alanines generated an artificial mutant, PTEN-4A, which remained “phospho-deficient” and therefore constitutively active. Interestingly, PTEN-4A suppressed cell proliferation and migration to a greater extent than PTEN-WT. PTEN-4A preferentially localized to the nucleus where it suppressed E2F-mediated transcription of cell cycle genes. PTEN physically interacted with the E2F1 protein and at E2F1-binding sites on chromatin, a likely mechanism for its transcriptional function. Further, deletion analysis on various PTEN domains revealed that the C2 domain of PTEN is indispensable for suppression of E2F-related genes. Systematic transcriptional promoter-reporter assays identified disease-associated C2 domain mutations that lose their ability to suppress E2F-mediated transcription, supporting the concept that these mutations are oncogenic in patients. Consistent with my findings, I observed increased level of PTEN phosphorylation and reduced nuclear PTEN levels in lung cancer patient samples. Further, to determine whether the enhanced growth-suppressive properties of PTEN-4A may be due to differential protein-protein interactions, I performed a comparative proteomic profiling of PTEN-WT and PTEN-4A interactomes using the SILAC methodology. Galectin-1 was identified as a candidate protein that binds preferentially to PTEN-WT and inhibits its tumor suppressive function. Taken together, the various tumor suppressive mechanisms of PTEN-4A may be harnessed therapeutically as adjunctive cancer therapy. Use of small molecule inhibitors that hinder PTEN C-tail phosphorylation is a plausible approach to activate PTEN function to reduce tumor burden.

<p>The PRLs are a subfamily of dual specificity phosphatases that appear to play important roles in oncogenesis. Much of the current understanding of PRL function has been either correlative, and deduced from observed PRL overexpression in pathological conditions, or from in vitro analysis of signaling pathways following PRL deletion or overexpression. Such studies, necessitated by the general lack of synthetic inhibitors or compounds to probe the substrate specificity and biological interactions of the PRLs, are nonetheless now providing critical insight into potential biological substrates and roles of the PRL phosphatases. The recent identification of PTEN as a substrate for PRL2 provided the foundation for studies to further define the role of PRL2 in oncogenesis and, by analogy, the normal physiological function of PRL2. In the studies described herein, a novel PRL2 conditional knock-out animal was generated and used to validate the PRL2/PTEN interaction in a leukemic phenotype, and further demonstrated that PRL2 inhibition can restore dysregulated PTEN/AKT pathways to significantly attenuate disease progression. Inhibition of PRL2 therefore represents a novel potential therapeutic strategy in the management and treatment of AML. This thesis project also sought to further examine the role of the PRLs in oncogenesis through their regulation and interaction of targets within the TME. Functional analyses revealed that PRL3 was the only PRL to have a prominent role in host response to TME development, and that previously proposed roles for PRL3 in angiogenesis and immune cell recruitment is dependent upon PRL3 expression and activity in cells external to the TME. The study also revealed a previously unrecognized synergism between VEGF and PRL3 in the host in promoting TME angiogenesis. The studies of PRL3 in the TME suggest the potential physiological role of PRL3 in wound healing.</p>

No description available.

No description available.

Astrocytes are emerging as important regulators of neural circuit function and behavior in the healthy and diseased nervous system. In a screen for astrocyte molecules that modulate neuronal hyperexcitability we identified multiple components of focal adhesion complexes (FAs) as potent suppressors of genetically- or pharmacologically-induced seizure-like activity. Depletion of astrocytic Tensin, b-integrin, Talin, Focal adhesion kinase (FAK), or matrix metalloproteinase 1 (Mmp1), which degrades extracellular matrix to activate b-integrin receptors, resulted in enhanced recovery from, or resistance to seizure activity. Reciprocally, promoting FA signaling by overexpression of Mmp1 in astrocytes led to enhanced-seizure severity. Blockade of FA signaling in astrocytes led to reduced-astrocytic coverage of the synaptic neuropil and reduced expression of the excitatory amino acid transporter EAAT1. However, upon seizure induction, depletion of FA signaling components resulted in enhanced astrocyte coverage of the synaptic neuropil and a ~2-fold increase in EAAT1 levels compared to controls. Our data indicate that FAs promote astrocyte coverage in neuropil and EAAT1 expression under normal physiological conditions, but in the context of hyperexcitability, FAs negatively regulate the extent of astrocytic processes within neuropil and EAAT1 expression, thereby inhibiting a more rapid recovery from conditions of excessive neuronal activity.

No description available.

G protein-coupled receptors (GPCRs) form the biggest family of membrane receptors and are involved in numerous physiological processes. Collectively, these receptors are also prominently targeted by the pharmaceutical industry due to their implications in multiple diseases and disorders. GPCR signaling is tightly regulated. Several kinases, activated downstream of the receptor, initiate negative feedback loops; and arrestins play a crucial role in these regulatory processes by desensitizing the ligand–activated receptor and promoting its endocytosis. By doing so, arrestins control the duration and the amplitude of signal transduction at the cell surface. In the last few years, several non-canonical roles have also been attributed to arrestins, such as the post-endocytic activation of several signalling pathways, or the regulation of crosstalks between GPCRs and various other signalling events. My thesis project was aimed at providing a better understanding of the non-canonical functions of arrestins. The first objective of my research work was to investigate a possible reciprocal effect of the activation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) on GPCR signaling. We demonstrated that stimulation of ERK1/2, either by a cell surface receptor or a constitutively active mutant, leads to a reduction in steady-state expression levels of many GPCRs at the cell surface. This receptor redistribution mechanism is dependent on beta-arrestins phosphorylation. In vitro kinase assays combined with complementation experiments in mouse embryonic fibroblasts (MEFs) lacking beta-arrestins, revealed that beta-arrestin-2 phosphorylation on Ser14 and Thr276 is essential for the ERK1/2-promoted GPCR sequestration. This ERK1/2- and arrestins mediated regulatory process was found to result in a global dampening of cell responsiveness. The second objective of my research work was to identify and develop a small organic compound that inhibits the interaction between arrestins and the adaptor protein AP-2, without interfering with the recruitment of arrestin to the receptor. This inhibitor, named Barbadin, was found to specifically block endocytic processes that are dependent on the interaction between arrestins and the appendage domain of the b-subunit of AP-2. We demonstrated its value as an analytical tool in studying the role of the arrestins in GPCR signaling, such as cAMP production and ERK1/2 activation. These results support the concept that beta-arrestin/AP-2-dependent signaling is important to both G protein-dependent and -independent pathways. The third objective of my research work was to develop a BRET-based biosensor able to detect signal-dependent PTEN conformational changes. This biosensor was validated by monitoring PTEN activation induced by targeted mutations affecting key intramolecular interactions or by modulating signalling pathways that impact PTEN function. We also demonstrated the value of this biosensor in studying PTEN/protein interactions using two known interactors that activate PTEN, beta-arrestin-2 and RhoA. Finally, we uncovered PTEN activation by several GPCRs, previously unknown as PTEN regulators. Given the central role of the tumor suppressor PTEN in oncogenesis, this biosensor could also provide a precious tool for anti-cancer drug research. To conclude, my research work highlighted non-canonical mechanisms for arrestins to activate GPCR-dependent signaling pathways, such as cAMP, ERK1/2 and PTEN, as well as negatively regulate GPCR signaling upon phosphorylation by ERK1/2. This work was made possible by the development of new tools: a beta-arrestin inhibitor named Barbadin and a PTEN BRET-based biosensor that have both shown their usefulness in studying beta-arrestin noncanonical signaling. / Les récepteurs couplés aux protéines G (RCPG) représentent la plus grande famille de récepteurs membranaires et sont impliqués dans un grand nombre de processus physiologiques. Cette famille de récepteurs constitue aussi une cible majeure dans la recherche pharmaceutique au vu de son importance dans de nombreuses pathologies. La signalisation des RCPG est étroitement régulée. Plusieurs kinases activées en aval du récepteur initient des boucles de régulation négative. Les arrestines jouent un rôle clé dans ces processus de régulation en favorisant la désensibilisation du récepteur activé par le ligand, suivie de son endocytose. Ainsi, les arrestines contrôlent la durée et l’amplitude de la transmission du signal à la surface de la cellule. Ces dernières années, plusieurs rôles non-canoniques ont été attribués aux arrestines comme l’activation de voies de signalisation post-endocytiques, ou la modulation de la régulation croisée entre les RCPG et d’autres acteurs de la signalisation cellulaire. Le premier objectif de mon travail de recherche est d’examiner l’effet réciproque de l’activation des kinases ERK1/2 (extracellular signal-regulated kinases 1/2) sur la signalisation des RCPG. Nous avons démontré que la stimulation de ERK1/2, soit par un récepteur de surface soit par l’utilisation d’un mutant constitutivement actif, conduit à la baisse de l’expression de surface basale de nombreux RCPG. Des essais kinases in vitro, combinés à des expériences de complémentation dans des fibroblastes embryonnaires de souris (MEF), où les gènes beta-arrestine-1/2 ont été supprimés, démontrent l’importance de la phosphorylation par ERK1/2 des résidus Ser14 et Thr276 dans ce mécanisme de séquestration des RCPG. Cette régulation, contrôlée par ERK1/2 et arrestine, conduit à une baisse globale de la capacité de réponse de la cellule aux stimuli extracellulaires. Le deuxième objectif de mon travail de recherche est d’identifier et de développer une petite molécule organique qui inhibe l’interaction entre l’arrestine et la protéine adaptatrice du complexe d’endocytose AP-2, sans toutefois empêcher la formation du complexe arrestine/récepteur. Cet inhibiteur, nommé Barbadin, bloque sélectivement les processus d’internalisation dépendants de l’interaction entre arrestine- et la sous-unité beta2 de la protéine adaptatrice AP-2. Barbadin représente le premier inhibiteur des fonctions d’arrestine, et nous avons démontré son utilité comme outil analytique pour déterminer la contribution des arrestines dans l’activation de plusieurs voies de signalisation en aval des RCPG, telles que la production d’AMP cyclique (AMPc) ou l’activation des kinases ERK1/2. Nos résultats démontrent l’importance du complexe arrestine/AP-2 dans la signalisation dépendante et indépendante des protéines G. Le troisième objectif de mon travail de recherche est de développer un biosenseur BRET capable de mesurer les changements de conformation du suppresseur de tumeur PTEN. Nous avons validé ce biosenseur en mesurant l’activation de PTEN suite à des mutations ciblées déstabilisant les interactions intramoléculaires au sein de cette protéine ou en modulant différentes voies de signalisation qui affectent sa fonction. Nous avons démontré l’intérêt de ce nouvel outil dans l’étude des interactions entre PTEN et des partenaires protéiques, en utilisant deux interacteurs connus pour activer PTEN : b-arrestine-2 et RhoA. Finalement, en utilisant ce biosenseur, nous avons démontré pour la première fois la capacité de plusieurs RCPG à induire l’activation de PTEN. Étant donné le rôle central de PTEN dans le développement tumoral, ce biosenseur constitue aussi un outil précieux pour la recherche de nouveaux médicaments anticancer. Ainsi, au travers de ces trois lignes directrices, nous avons pu mettre en lumière de nouveaux rôles non-canoniques des arrestines, soit dans l’activation de voies de signalisation, (comme la production d’AMPc, l’activation de ERK1/2 ou de PTEN), soit comme régulateur négatif de la signalisation des RCPG après phosphorylation par ERK1/2. Ce travail a été rendu possible par le développement de nouveaux outils pour l’étude des RCPG : un inhibiteur de beta-arrestine, Barbadin, et un biosenseur BRET de PTEN ; tous deux ayant démontré leur utilité dans l’étude des voies de signalisation non-canoniques des arrestines.